Policy & Regulation
Nitrome Biosciences secures Michael J. Fox Foundation Target Advancement grant
13 June 2019 -

Nitrome Biosciences on Wednesday announced a Target Advancement grant from The Michael J. Fox Foundation for the advancement of Parkinson's Research (MJFF) through the company's alpha-synuclein pathway.

The company is developing drugs against a new class of enzymes, initially targeting Parkinson's disease. Alpha-synuclein nitration and aggregation, a hallmark of Parkinson's, is catalyzed by a newly identified enzyme, called Synuclein Nitrase. The drugs are intended to inhibit Synuclein Nitrase and slow or halt Parkinson's disease progression.

Nitrome Biosciences will use the funds to accelerate its biological studies on a new drug target for Parkinson's disease.

The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition. It pursues its goals through funded, highly targeted research programme coupled with active global engagement of scientists, Parkinson's patients, business leaders as well as clinical trial participants, donors and volunteers.